High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the recently published Lipitor's Effect in Alzheimer's Dementia (LEADe) trial, which included 640 randomized patients with mild Alzheimer disease, intensive lipid lowering by the addition of atorvastatin (80 mg) to donepezil did not improve cognitive function over a 72-week period.464”
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [438]
In the citing paper
“Following stroke or TIA, 34 patients are at risk not only of recurrent cerebrovascular events but also of other major CV events including MI.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [34]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [428]
In the citing paper
“Many reports have also indicated that there is no clear relationship between the TG level and cerebrovascular disease856, 862, 863).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [862]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Research works printed but not linked: 1
- Waters DD, 2005, Circulation, 112, 2020
Cited by
Items 201–300 of 1,005
Everett, B. M., Glynn, R. J., MacFadyen, J. G., & Ridker, P. M. (2010) · Circulation · doi:10.1161/circulationaha.109.874834 · Cited by 170
Boulanger, M., Béjot, Y., Rothwell, P. M., & Touzé, E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007267 · Cited by 169
Update in Intracerebral Hemorrhage
Aguilar, M. I., & Brott, T. G. (2011) · The Neurohospitalist · doi:10.1177/1941875211409050 · Cited by 163
Delahoy, P. J., Magliano, D. J., Webb, K., Grobler, M., & Liew, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.017 · Cited by 168
Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis
Bang, O. Y., Saver, J. L., Liebeskind, D. S., Starkman, S., Villablanca, P., Salamon, N., Buck, B., Ali, L., Restrepo, L., Vinuela, F., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000252799.64165.d5 · Cited by 166
Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis
Upadhyay, A., Earley, A., Lamont, J. L., Haynes, S., Wanner, C., & Balk, E. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-4-201208210-00005 · Cited by 166
Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke
Bonaventura, A., Liberale, L., Vecchié, A., Casula, M., Carbone, F., Dallegri, F., & Montecucco, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121967 · Cited by 166
An assessment by the Statin Intolerance Panel: 2014 update
Guyton, J. R., Bays, H. E., Grundy, S. M., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.002 · Cited by 165
Vergouwen, M. D. I., de Haan, R. J., Vermeulen, M., & Roos, Y. B. W. E. M. (2008) · Stroke · doi:10.1161/strokeaha.107.488791 · Cited by 166
Implications of vascular endothelial growth factor for postischemic neurovascular remodeling
Hermann, D. M., & Zechariah, A. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.100 · Cited by 162
“…(Stroke Prevention by Aggressive Reduction in Cholesterol Levels) study, which is a phase III trial in patients with recent stroke or transient ischemic attack (Amarenco et al, 2006), atorvastatin does not exhibit any unfavorable side effects such as brain edema or hemorrhagic transformation.”
BackgroundA new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion
Shi, L., Rocha, M., Leak, R. K., Zhao, J., Bhatia, T. N., Mu, H., Wei, Z., Yu, F., Weiner, S. L., Ma, F., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18798162 · Cited by 161
Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome
Rivero-Arias, O., Ouellet, M., Gray, A., Wolstenholme, J., Rothwell, P. M., & Luengo-Fernandez, R. (2010) · Medical Decision Making · doi:10.1177/0272989x09349961 · Cited by 161
Writing Committee Members, Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. B., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182112d08 · Cited by 161
Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00040-8 · Cited by 161
“Only two trials 17,18 allowed for direct assessments of high-intensity statin versus placebo, but indirect assessments of the effects of high-intensity statin therapy were calculated as described previously.”
Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv072 · Cited by 160
2017 Taiwan lipid guidelines for high risk patients
Li, Y.-H., Ueng, K.-C., Jeng, J.-S., Charng, M.-J., Lin, T.-H., Chien, K.-L., Wang, C.-Y., Chao, T.-H., Liu, P.-Y., Su, C.-H., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 157
Kelly, P. J., Lemmens, R., Weimar, C., Walsh, C., Purroy, F. F., Barber, M., Collins, R., Cronin, S., Członkowska, A., Desfontaines, P., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00968-1 · Cited by 180
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s4324 · Cited by 189
Flint, A. C., Kamel, H., Navi, B. B., Rao, V. A., Faigeles, B. S., Conell, C. A., Klingman, J. G., Sidney, S., Hills, N. K., Sorel, M. E., et al. (2011) · Stroke · doi:10.1161/strokeaha.111.627729 · Cited by 158
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Chauvin, B., Drouot, S., Barrail‐Tran, A., & Taburet, A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0075-4 · Cited by 156
“Several clinical trials have demonstrated the benefit of statins for patients without a history of coronary heart disease (primary prevention) [50–54] and for patients with documented coronary heart disease (secondary prevention) [55–58].”
BackgroundRisk factors for intracerebral hemorrhage differ according to hemorrhage location
Martini, S. R., Flaherty, M. L., Brown, W. M., Haverbusch, M. A., Comeau, M. E., Sauerbeck, L. R., D, B. M. K. M., Deka, R., Kleindorfer, D., Moomaw, C. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318276896f · Cited by 172
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Morofuji, Y., Nakagawa, S., Ujifuku, K., Fujimoto, T., Otsuka, K., Niwa, M., & Tsutsumi, K. (2022) · Pharmaceuticals · doi:10.3390/ph15020151 · Cited by 151
Lip, G. Y. H., Lane, D. A., Lenarczyk, R., Boriani, G., Doehner, W., Benjamin, L. A., Fisher, M., Lowe, D., Sacco, R. L., Schnabel, R. B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac245 · Cited by 175
ElAli, A., Doeppner, T. R., Zechariah, A., & Hermann, D. M. (2011) · Stroke · doi:10.1161/strokeaha.111.615559 · Cited by 150
Noda, H., Iso, H., Irie, F., Sairenchi, T., Ohtaka, E., Doi, M., Izumi, Y., & Ohta, H. (2009) · Circulation · doi:10.1161/circulationaha.108.795666 · Cited by 150
Statin‐associated autoimmune myopathy and anti‐HMGCR autoantibodies
Mohassel, P., & Mammen, A. L. (2013) · Muscle & Nerve · doi:10.1002/mus.23854 · Cited by 155
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Lee, M., Saver, J. L., Liao, H.-W., Lin, C.-H., & Ovbiagele, B. (2017) · Stroke · doi:10.1161/strokeaha.116.013977 · Cited by 147
Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007.
George, M. G., Tong, X., McGruder, H. F., Yoon, P. W., Rosamond, W. D., Winquist, A. G., Hinchey, J. A., Wall, H. K., & Pandey, D. K. (2009) · PubMed · Cited by 149
Thanassoulis, G., Williams, K., Ye, K., Brook, R., Couture, P., Lawler, P. R., de Graaf, J., Furberg, C. D., & Sniderman, A. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000759 · Cited by 148
LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
Ravnskov, U., de Lorgeril, M., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., Kendrick, M. E., Langsjoen, P. H., Mascitelli, L., et al. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1519391 · Cited by 171
Allara, E., Morani, G., Carter, P., Gkatzionis, A., Zuber, V., Foley, C. N., Rees, J. M. B., Mason, A. M., Bell, S., Gill, D., et al. (2019) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.119.002711 · Cited by 145
Reduction in Blood Pressure With Statins Results From the UCSD Statin Study, a Randomized Trial
Golomb, B. A., Dimsdale, J. E., White, H. L., Ritchie, J. B., & Criqui, M. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.7.721 · Cited by 148
Statin use and the risk of developing diabetes: a network meta‐analysis
Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4020 · Cited by 144
Lee, M., Cheng, C.-Y., Wu, Y., Lee, J.-D., Hsu, C., & Ovbiagele, B. I. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5578 · Cited by 166
Understanding the molecular mechanisms of statin pleiotropic effects
German, C. A., & Liao, J. K. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03492-6 · Cited by 177
Bohula, E. A., Wiviott, S. D., Giugliano, R. P., Blazing, M. A., Park, J.-G., Murphy, S. A., White, J. A., Mach, F., Van de Werf, F., Dalby, A. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029095 · Cited by 142
Cardiovascular effects of statins, beyond lipid-lowering properties
Mihos, C. G., Pineda, A. M., & Santana, O. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.009 · Cited by 162
Kwon, S. U., Hong, K., Kang, D., Park, J., Lee, J.-H., Cho, Y., Yu, K., Koo, J.-S., Wong, K. S., Lee, S., et al. (2011) · Stroke · doi:10.1161/strokeaha.110.609370 · Cited by 140
Cholesterol and cardiovascular disease in the elderly. Facts and gaps.
Félix-Redondo, F. J., Grau, M., & Fernandez-Berges, D. J. (2013) · Europe PMC (PubMed Central) · Cited by 195
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Hyperlipidemia and Reduced White Matter Hyperintensity Volume in Patients With Ischemic Stroke
Jiménez-Conde, J., Biffi, A., Rahman, R. M. A., Kanakis, A. S., Butler, C., Sonni, S., Massasa, E. E., Cloonan, L. K., Gilson, A. J., Capozzo, K., et al. (2010) · Stroke · doi:10.1161/strokeaha.109.563502 · Cited by 145
Goldstein, L. B., Amarenco, P., Zivin, J. A., Messig, M., Altafullah, I., Callahan, A., Hennerici, M. G., MacLeod, M. J., Sillesen, H. H., Zweifler, R. M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.557330 · Cited by 141
Nitric Oxide: Considerations for the Treatment of Ischemic Stroke
Terpolilli, N. A., Moskowitz, M. A., & Plesnila, N. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.12 · Cited by 150
The neurovascular unit and combination treatment strategies for stroke
Zhang, L., Zhang, Z. G., & Chopp, M. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.006 · Cited by 144
Dhamoon, M. S., Tai, W., Boden-Albala, B. M., Rundek, T., Paik, M. C., Sacco, R. L., & Elkind, M. S. V. (2007) · Stroke · doi:10.1161/strokeaha.106.480988 · Cited by 146
Labreuche, J., Touboul, P., & Amarenco, P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.040 · Cited by 150
“Blood cholesterol is a well-established risk factor for cardiovasular disease [1], whereas its relationship with fatal stroke is more ontroversial [2,3] despite the benefit of lipid-lowering therapy n preventing stroke events [4,5].”
BackgroundWang, Y., Liu, M., & Pu, C. (2017) · International Journal of Stroke · doi:10.1177/1747493017694391 · Cited by 143
Lackland, D. T., Elkind, M. S. V., D’Agostino, R. B., Dhamoon, M. S., Goff, D. C., Higashida, R. T., McClure, L. A., Mitchell, P. H., Sacco, R. L., Sila, C. A., et al. (2012) · Stroke · doi:10.1161/str.0b013e31825bcdac · Cited by 161
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
Jukema, J. W., Zijlstra, L. E., Bhatt, D. L., Bittner, V. A., Diaz, R., Drexel, H., Goodman, S. G., Kim, Y.-U., Pordy, R., Reiner, Ž., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.043826 · Cited by 133
Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications
Levine, D. A., & Langa, K. M. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0047-z · Cited by 141
New‐Onset Epilepsy Risk Factors in Older Veterans
Pugh, M. J., Knoefel, J. E., Mortensen, E. M., Amuan, M. E., Berlowitz, D. R., & Cott, A. C. V. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.02124.x · Cited by 128
Statin Use Following Intracerebral Hemorrhage: A Decision Analysis
Westover, M. B., Bianchi, M. T., Eckman, M. H., & Greenberg, S. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.356 · Cited by 136
Platelets and their chemokines in atherosclerosis—clinical applications
von Hundelshausen, P., & Schmitt, M. M. N. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00294 · Cited by 148
Chang, R. W., Tucker, L.-Y. S., Rothenberg, K. A., Lancaster, E. M., Faruqi, R. M., Kuang, H. C., Flint, A. C., Avins, A. L., & Nguyen‐Huynh, M. N. (2022) · JAMA · doi:10.1001/jama.2022.4835 · Cited by 143
Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke
Karagiannis, A. I., Mikhailidis, D. P., Τζιόμαλος, Κ., Sileli, M. N., Savvatianos, S., Kakafika, A. I., Gossios, T. D., Krikis, N., Moschou, I., Xochellis, M., et al. (2007) · Circulation Journal · doi:10.1253/circj.71.1120 · Cited by 132
Hosomi, N., Nagai, Y., Kohriyama, T., Ohtsuki, T., Aoki, S., Nezu, T., Maruyama, H., Sunami, N., Yokota, C., Kitagawa, K., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.006 · Cited by 132
Leoo, T., Lindgren, A. G., Petersson, J., & von Arbin, M. (2008) · Cerebrovascular Diseases · doi:10.1159/000113864 · Cited by 124
Hypercholesterolaemia and vascular dementia
Appleton, J. P., Scutt, P., Sprigg, N., & Bath, P. M. (2017) · Clinical Science · doi:10.1042/cs20160382 · Cited by 149
Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population
Varbo, A., Nordestgaard, B. G., Tybjærg‐Hansen, A., Schnohr, P., Jensen, G. B., & Benn, M. (2011) · Annals of Neurology · doi:10.1002/ana.22384 · Cited by 122
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 322
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)
Committee for the Korean Guidelines for the Management of Dyslipidemia (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.3.275 · Cited by 132
Tramacere, I., Boncoraglio, G. B., Banzi, R., Giovane, C. D., Kwag, K. H., Squizzato, A., & Moja, L. (2019) · BMC Medicine · doi:10.1186/s12916-019-1298-5 · Cited by 140
Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial
Montaner, J., Chacón, P. M., Krupiński, J., Rubio, F. J., Millán, M., Molina, C. A., Hereu, P., Quintana, M., & Álvarez‐Sabín, J. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.02015.x · Cited by 123
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders
Lanznaster, D., Dal-Cim, T. A., Piermartiri, T., & Tasca, C. I. (2016) · Aging and Disease · doi:10.14336/ad.2016.0208 · Cited by 136
Circulating Lipoprotein Lipids, Apolipoproteins and Ischemic Stroke
Yuan, S., Tang, B., Zheng, J., & Larsson, S. C. (2020) · Annals of Neurology · doi:10.1002/ana.25916 · Cited by 129
Statin enhancement of collateralization in acute stroke
Ovbiagele, B. I., Saver, J. L., Starkman, S., Kim, D., Ali, L. K., Jahan, R., Duckwiler, G., Viñuela, F. V., Pineda, S., & Liebeskind, D. S. (2007) · Neurology · doi:10.1212/01.wnl.0000264931.34941.f0 · Cited by 120
Ischemic Stroke in South Asians
Gunarathne, A., Patel, J. V., Gammon, B., Gill, P. S., Hughes, E. A., & Lip, G. Y. H. (2009) · Stroke · doi:10.1161/strokeaha.108.535724 · Cited by 120
Trends and Risk Factors Associated With Stroke Recurrence in China, 2007-2018
Xu, J., Zhang, X., Jin, A., Pan, Y., Li, Z., Meng, X., & Wang, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.16341 · Cited by 131
Experimental treatments for acute ischaemic stroke
Sacco, R. L., Chong, J. Y., Prabhakaran, S., & Elkind, M. S. V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60155-x · Cited by 123
Olsen, T. S., Christensen, R. H. B., Kammersgaard, L. P., & Andersen, K. K. (2007) · Stroke · doi:10.1161/strokeaha.107.490292 · Cited by 119
Odden, M. C., Pletcher, M. J., Coxson, P. G., Thekkethala, D., Guzman, D., Heller, D. J., Goldman, L., & Bibbins-Domingo, K. B. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1430 · Cited by 128
Chimowitz, M. I., Lynn, M., Turan, T. N., Fiorella, D., Lane, B. F., Janis, S., & Derdeyn, C. P. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.05.001 · Cited by 135
Chróinín, D. N., Callaly, E. L., Duggan, J., Merwick, Á., Hannon, N., Sheehan, O. C., Marnane, M., Horgan, G., Williams, E. B., Harris, D., et al. (2011) · Stroke · doi:10.1161/strokeaha.110.596734 · Cited by 121
Intracranial atherosclerotic disease: An update
Qureshi, A. I., Feldmann, E. G., Gomez, C. R., Johnston, S. C., Kasner, S. E., Quick, D. C., Rasmussen, P. A., Suri, M. F. K., Taylor, R. A., & Zaidat, O. O. (2009) · Annals of Neurology · doi:10.1002/ana.21768 · Cited by 122
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820d8c98 · Cited by 147
Lipids and Lipid Mediators Associated with the Risk and Pathology of Ischemic Stroke
Kłoska, A., Malinowska, M., Gabig‐Cimińska, M., & Jakóbkiewicz‐Banecka, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103618 · Cited by 124
Shoamanesh, A., Lindsay, M. P., Castellucci, L. A., Cayley, A., Crowther, M. A., de Wit, K., English, S. W., Hoosein, S., Huynh, T. J., Kelly, M., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493020968424 · Cited by 141
A practical approach to the management of cerebral amyloid angiopathy
Kozberg, M. G., Perosa, V., Gurol, M. E., & van Veluw, S. J. (2020) · International Journal of Stroke · doi:10.1177/1747493020974464 · Cited by 133
Rudilosso, S., Rodríguez-Vázquez, A., Urra, X., & Arboix, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031497 · Cited by 123
Steiner, T., Purrucker, J. C., de Sousa, D. A., Apostolaki‐Hansson, T., Beck, J., Christensen, H., Cordonnier, C., Downer, M. B., Eilertsen, H., Gartly, R., et al. (2025) · European Stroke Journal · doi:10.1177/23969873251340815 · Cited by 164
Coutts, S. B., Eliasziw, M., Hill, M. D., Scott, J. N., Subramaniam, S., Buchan, A. M., & Demchuk, A. M. (2008) · International Journal of Stroke · doi:10.1111/j.1747-4949.2008.00182.x · Cited by 115
Molecular basis of statin-associated myopathy
Vaklavas, C., Chatzizisis, Y. S., Ziakas, A., Zamboulis, C., & Giannoglou, G. D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.021 · Cited by 128
Therapeutic potential of statins in Alzheimer's disease
Kandiah, N., & Feldman, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.352 · Cited by 122
Review: Stroke prevention: modifying risk factors
Romero, J. R., Morris, J. G., & Pikula, A. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708093847 · Cited by 152
Callahan, A., Amarenco, P., Goldstein, L., Sillesen, H., Messig, M., Samsa, G., Altafullah, I., Ledbetter, L., Macleod, M., Scott, R. S., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.146 · Cited by 127
Statins and the risk of new-onset diabetes: a review of recent evidence
Preiss, D., & Sattar, N. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834b4994 · Cited by 125
Recurrent Ischemic Stroke: Strategies for Prevention.
Oza, R., Rundell, K., & Garcellano, M. (2017) · PubMed · Cited by 110
Emerging views of statin pleiotropy and cholesterol lowering
Yu, D., & Liao, J. K. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab032 · Cited by 120
Multi-omics approaches for revealing the complexity of cardiovascular disease
Doran, S., Arif, M., Lam, S., Bayraktar, A., Turkez, H., Uhlen, M., Boren, J., & Mardinoglu, A. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab061 · Cited by 109
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 128
Intracerebral haemorrhage — mechanisms, diagnosis and prospects for treatment and prevention
Seiffge, D. J., Fandler‐Höfler, S., Du, Y., Goeldlin, M. B., Jolink, W. M. T., Klijn, C. J. M., & Werring, D. J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01035-w · Cited by 130
Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients
Sirimarco, G., Labreuche, J., Bruckert, É., Goldstein, L. B., Fox, K. M., Rothwell, P. M., Amarenco, P., Bousser, M., Chamorro, Á., Ford, I., et al. (2014) · Stroke · doi:10.1161/strokeaha.113.004229 · Cited by 119
Mok, V., Lam, W. W. M., Fan, Y., Wong, A., Ng, P. W., Tsoi, T. H., Yeung, M. W., & Wong, K. S. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5008-7 · Cited by 120
“More recently, the SPARCL (stroke prevention by aggressive reduction in cholesterol levels) study showed that statins reduced stroke and other cardiovascular events in patients with stroke yet without known CHD [19].”
BackgroundWhat Should We Do with Asymptomatic Carotid Stenosis?
Abbott, A. L., Bladin, C. F., Levi, C. R., & Chambers, B. R. (2007) · International Journal of Stroke · doi:10.1111/j.1747-4949.2007.00096.x · Cited by 116
Jafri, H., Alsheikh-Ali, A. A. A., & Karas, R. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-12-201012210-00006 · Cited by 111
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
Davis, S. M., & Donnan, G. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1107281 · Cited by 104
Treatment of Carotid Artery Stenosis: Medical Therapy, Surgery, or Stenting?
Lanzino, G. S., Rabinstein, A. A., & Brown, R. D. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60546-6 · Cited by 104
Neuroprotection for traumatic brain injury
Loane, D. J., Stoica, B. A., & Faden, A. I. (2015) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52892-6.00022-2 · Cited by 109
Metadata
- Authors
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Affiliations
- Université Paris Diderot (FR)
- Corresponding author
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-08-10
- Volume
- 355
- Issue
- 6
- Pages
- 549-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1546258268
- Cited by
- 2,887
- References
- 21
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 119 · 2023: 112 · 2022: 135 · 2021: 134 · 2020: 139 · 2019: 140 · 2018: 129 · 2017: 132 · 2016: 139 · 2015: 125 · 2014: 142 · 2013: 160 · 2012: 149
- FWCI
- 200.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atorvastatin, high-intensity statin therapy, stroke, transient ischemic attack, secondary stroke prevention, LDL cholesterol lowering, hemorrhagic stroke, ischemic stroke, cardiovascular events, elevated liver enzymes, lipid-lowering therapy, mortality, serious adverse events
- MeSH terms
- Atorvastatin, Adult, Cardiovascular Diseases, Cerebral Hemorrhage, Cerebral Infarction, Ischemic Attack, Transient, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Risk, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.